Central nervous system effects of high-dose cytosine arabinoside
Herzig, R.H.; Herzig, G.P.; Wolff, S.N.; Hines, J.D.; Fay, J.W.; Phillips, G.L.
Seminars in Oncology 14(2 Suppl 1: 21-24
1987
ISSN/ISBN: 0093-7754 PMID: 3589694 Document Number: 304789
Document emailed within 1 workday
Related Documents
Osugi, Y.; Keisei, K.H.; Murayama, N.; Inoue, M.; Ishihara, S.; Hara, J.; Yagi, K.; Tawa, A.; Okada, S.; Izumi, Y. 1990: Effects of recombinant human granulocyte colony stimulating factor following high-dose cytosine arabinoside therapy in children with malignancy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 17(7): 1379-1382Sanz, M.A.; Martínez, J.; Borrego, D.; Martín-Aragonés, G.; Lorenzo, I.; Sanz, G.; Sayas, M.J.; Jarque, I.; Pastor, E.; Rafecas, J. 1987: High-dose cytosine arabinoside and mitoxantrone in high-risk acute nonlymphoblastic leukemia Seminars in Oncology 14(2 Suppl 1): 18-20
Klener, P.; Háber, J. 1985: Treatment of refractory leukemia with high-dose cytosine arabinoside Neoplasma 32(1): 113-117
Nemet, D.; Labar, B.; Bogdanić, V.; Hauptman, E.; Jaksić, B.; Minigo, H.; Sertić, D.; Mrsić, M.; Pavletić, Z.; Kovacević, J. 1989: High dose cytosine arabinoside in the treatment of adult acute myelogenous leukaemia Bone Marrow Transplantation 4(Suppl 3): 42-44
Keating, M.J.; Estey, E.; Plunkett, W.; Iacoboni, S.; Walters, R.; Kantarjian, H.; Andersson, B.; Beran, M.; McCredie, K.B.; Freireich, E.J. 1985: Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital Seminars in Oncology 12(2 Suppl. 3): 98-104
Ohshima, A.; Yoshida, K.; Sato, T.; Miyazaki, S.; Yanagisawa, M.; Nakayama, Y.; Takahashi, T.; Mamiya, S.; Fukusima, Y.; Miura, A.B. 1987: Intermediate- and high-dose cytosine arabinoside therapy in acute refractory leukemia Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(1): 192-195
Wysocki, M.; Nowaczyk-Michalak, A.; Pilecki, O.; Trybuś, L.; Balcar-Boroń, A. 1992: Jaundice following high--dose arabinoside cytosine in a child with acute myelogenous leukemia Acta Haematologica Polonica 23(3): 197-199
Johnson, N.T.; Crawford, S.W.; Sargur, M. 1987: Acute acquired demyelinating polyneuropathy with respiratory failure following high-dose systemic cytosine arabinoside and marrow transplantation Bone Marrow Transplantation 2(2): 203-207
Herzig, R.H.; Coccia, P.F.; Lazarus, H.M.; Strandjord, S.E.; Graham-Pole, J.; Cheung, N.K.; Gordon, E.M.; Gross, S.; Spitzer, T.R.; Warkentin, P.I. 1985: Bone marrow transplantation for acute leukemia and lymphoma with high-dose cytosine arabinoside and total body irradiation Seminars in Oncology 12(2 Suppl 3: 184-186
Ghaddar, H.M.; Plunkett, W.; Kantarjian, H.M.; Pierce, S.; Freireich, E.J.; Keating, M.J.; Estey, E.H. 1994: Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside Leukemia 8(8): 1269-1274
Nagatoshi, Y.; Okamura, J.; Ikuno, Y.; Akamatsu, M.; Tasaka, H. 1997: Therapeutic trial of intensified conditioning regimen with high-dose cytosine arabinoside, cyclophosphamide and either total body irradiation or busulfan followed by allogeneic bone marrow transplantation for myelodysplastic syndrome in children International Journal of Hematology 65(3): 269-275
Hines, J.D.; Mazza, J.J.; Oken, M.M.; Bennett, J.M.; Adelstein, D.J.; Keller, A.; O'Connell, M.J. 1985: High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase i Pilot Study for the Eastern Cooperative Oncology Group Seminars in Oncology 12(2 Suppl 3: 117-119
Giannone, L.; Wolff, S.N. 1987: Phase Ii treatment of central nervous system gliomas with high-dose etoposide and autologous bone marrow transplantation Cancer Treatment Reports 71(7-8): 759-761
Gaspar, N.; Boudou, P.; Haroche, J.; Wechsler, B.; Van Den Neste, E.; Hoang-Xuan, K.; Amoura, Z.; Guillevin, R.; Savatovski, J.; Azar, N.; Piette, J-Charles.; Leblond, Véronique. 2006: High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for adult histiocytic disorders with central nervous system involvement Haematologica 91(8): 1121-1125
Gallo, J.H.; Rozenberg, M.C. 1986: Response of refractory anemia to low-dose cytosine arabinoside Australian and New Zealand Journal of Medicine 16(2): 231-233
Takemoto, Y.; Sampi, K.; Kuraishi, Y.; Okabe, K.; Tamura, K.; Mizoguchi, H.; Saito, H.; Masaoka, T.; Ogawa, M. 1999: A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. the KRN8602 Leukemia Study Group International Journal of Hematology 70(1): 20-25
Lin, S.F.; Liu, H.W.; Chen, T.P. 1990: Chemotherapy for acute non-lymphocytic leukemia with low-dose cytosine arabinoside (Ara-C) Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 53(1): 45-50
Pedersen, G.; Stentoft, J.; Pedersen, J.O.; Jensen, M.K. 1994: Treatment of acute myeloid leukemia in the elderly with low-dose cytosine arabinoside Ugeskrift for Laeger 156(43): 6380-6384
Wakita, A.; Murase, T.; Uchida, T.; Fujiwara, Y.; Tanaka, M.; Ohkita, T. 1992: Mitoxantrone and conventional-dose cytosine arabinoside for relapsed and refractory acute leukemia Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(5): 653-657
Kobayashi, S.; Sakai, H.; Tomiazwa, T.; Koiso, H.; Kim, K.; Ueki, K.; Tamura, J.; Yano, S.; Naruse, T.; Karasawa, M. 1999: Successful low-dose cytosine arabinoside treatment in a patient with acute leukemia from idiopathic myelofibrosis Journal of Medicine 30(1-2): 101-109